| 23rd week of 2013 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20130143895 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS - The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3. | 2013-06-06 |
| 20130143896 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY - The present invention relates to substituted isoxazolo-quinazolines which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular human MPS1 and PERK. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them. | 2013-06-06 |
| 20130143897 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BLONANSERIN - An oral controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) and optionally pharmaceutically acceptable excipients is provided. The present invention further relates to a controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) such that the composition releases not less than about 80% of Blonanserin within 20 hours, when dissolution is carried out in 900 ml, 0.1 N HCl, USP apparatus Type II (Paddle) at 50 rpm for 20 hrs. The controlled release pharmaceutical composition of the invention releases 50% of Blonanserin between about 4 to 14 hours, when dissolution is carried out in 900 ml, 0.1 N HCl, USP apparatus Type II (Paddle) at 50 rpm. | 2013-06-06 |
| 20130143898 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 2013-06-06 |
| 20130143899 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R | 2013-06-06 |
| 20130143900 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines - The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) | 2013-06-06 |
| 20130143901 | COMBINATION OF PIMAVANSERIN AND RISPERIDONE FOR THE TREATMENT OF PSYCHOSIS - Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic. | 2013-06-06 |
| 20130143902 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE - Provided are methods that relate to a novel therapeutic strategy for the treatment of cancers. In particular, the method comprises administration of Compound A, | 2013-06-06 |
| 20130143903 | REMEDY FOR MIGRAINE HEADACHE - A medicated formulation and method of use for treating migraine having a combination of active ingredients including: nicotine, and tryptophan alone and also with phenylalanine and/or, tyrosine, and/or caffeine in an aqueous solution. | 2013-06-06 |
| 20130143904 | COMPOSITION FOR INHIBITING THE ACTIVITY OF INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR SUBTYPE III - An agent for inhibiting the activity of inositol-1,4,5-triphospate receptor subtype 3 (IP | 2013-06-06 |
| 20130143905 | NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (I) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. | 2013-06-06 |
| 20130143906 | SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS - The present disclosure provides pyrimidinone-phenyl-pyrimidinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and inflammatory disease, having the structure of Formula (I): | 2013-06-06 |
| 20130143907 | PYRAZOLOQUINOLINE DERIVATIVES - A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. | 2013-06-06 |
| 20130143908 | METHOD FOR PREPARING ROSUVASTATIN CALCIUM INTERMEDIATE - A method for preparing a rosuvastatin calcium intermediate represented by formula I. The method includes: hydrolyzing an ester compound represented by formula II (in which, R represents C1-C5) in the presence of a metal compound to obtain a carboxylic acid compound represented by formula III; and reducing the carboxylic acid compound in the presence of a reductant. | 2013-06-06 |
| 20130143909 | Acid Salt Forms of Polymer-Drug Conjugates and Alkoxylation Methods - Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate. | 2013-06-06 |
| 20130143910 | Fructose-1,6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis - A method and composition for treating cancer cells that targets fructose-1,6-biphosphataseenzymes (FBPs, type 1 and type 2) and/or their respective pathways. In one embodiment, inhibitors of FBPs or FBPs pathways are administered to a patient to treat brain cancer metastasis. In another embodiment, the present invention is particularly well suited for treating cancer cells that generally survive under glucose-independent conditions, or any other condition where cancer cells produce glucose via FBPs mediated pathways. | 2013-06-06 |
| 20130143911 | MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors - Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided. | 2013-06-06 |
| 20130143912 | SUBLINGUAL ZOLPIDEM FORMULATIONS - The present disclosure provides pharmaceutical compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the compositions devoid of buffer and in the presence of alkaline oxides capable of raising the pH of saliva to a pH greater than about 7.0 thereby facilitate the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided. | 2013-06-06 |
| 20130143913 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS - An object of the present invention is to provide an agent for prevention or treatment of a fatty liver disease, preferably NAFLD, more preferably NASH. The present invention provides an agent for prevention or treatment of a fatty liver disease containing ibudilast as an active agent. | 2013-06-06 |
| 20130143914 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT - Compounds of formula (I) are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory wherein R | 2013-06-06 |
| 20130143915 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS - The present invention relates to compounds of Formula (I), wherein R | 2013-06-06 |
| 20130143916 | COMPOUND LIBRARIES MADE THROUGH PHOSPHINE-CATALYZED ANNULATION/TEBBE/DIELS-ALDER REACTIONS - A method for producing libraries of structurally and stereochemically diverse molecules that can be screened for biological or chemical activity. A library of 91 heterocyclic compounds composed of 16 distinct scaffolds was synthesized through a sequence of phosphine-catalyzed ring-forming reactions, Tebbe reactions, Diels-Alder reactions, and, in some cases, hydrolysis to illustrate the methods. Three compounds inhibiting migration of human breast cancer cells are identified from the library. | 2013-06-06 |
| 20130143917 | (2E)-3-PHENYL-N-[2,2,2-TRIFLUORO-1-[[8-QUINOLINEAMINO)THIOMETHYL]AMINO]ETH- YL]-2-ACRYLAMIDE AND PHARMACEUTICAL USES THEREOF - The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis | 2013-06-06 |
| 20130143918 | Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl-6-F- luoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxa- mide - The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith. | 2013-06-06 |
| 20130143919 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis. | 2013-06-06 |
| 20130143920 | Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia. - Methods for treatment of diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including myeloproliferative neoplasia, chronic myeloid leukemia, and acute myeloid leukemia. | 2013-06-06 |
| 20130143921 | NOVEL PEPERIDINE-FLAVAN ALKALOID COMPOUNDS DERIVED FROM AFRICAN HERB TEA KINKELIBA AS ANTI-DIABETIC AGENTS - This invention provides the methods of separation and identification of a novel type of piperidine flavan alkaloids from an African herbal tea, the leaves of | 2013-06-06 |
| 20130143922 | THIO COMPOUNDS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 2013-06-06 |
| 20130143923 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION - The present invention related to crystalline forms of thalidomide having a high polymorphic purity and to processes for their preparation. The present invention also relates to pharmaceutical preparations comprising the crystalline forms for the treatment of patients suffering from autoimmune, inflammatory or angiogenic disorders. | 2013-06-06 |
| 20130143924 | COMPOSITION FOR REPELLING AND DETERRING VERMIN - The present invention is directed to a non-therapeutical process for deterring vermin, which is based on the usage of the largely known beta amino-alcohol derivatives of formula (I) | 2013-06-06 |
| 20130143925 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE - Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. | 2013-06-06 |
| 20130143926 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS - The invention provides a compound which is (a) a phenylamide derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate, prodrug or solvate thereof: wherein R | 2013-06-06 |
| 20130143927 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2013-06-06 |
| 20130143928 | BIS-PYRINIDIUM COMPOUNDS - A method of treating, inhibiting, or preventing an infection in a subject is described. The method comprises administering to the subject an effective amount of at least one bis-pyridinium compound. The bis-pyridinium compound comprises two aromatic ring structures. Each of the ring structures comprises a pyridine ring, and the ring structures are linked by a linker group of at least 8 atoms in length, said linker group being attached to the nitrogen atoms of the pyridine rings. At least one substituent on at least one of the ring structures is an alkyl group having at least 2 carbon atoms, and no substituent on either of the ring structures is —OH, —SH or an amine group. | 2013-06-06 |
| 20130143929 | FUNGICIDAL IMIDAZOLES - Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, | 2013-06-06 |
| 20130143930 | ACTIVATION OF AMP-PROTEIN ACTIVATED KINASE BY OXALOACETATE COMPOUNDS - The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer. | 2013-06-06 |
| 20130143931 | 5-[5-[2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-METHYLPROPANOMETHYLPROPANOYLMET- HYLAMINO]-4-(4-FLUORO-2-METHYLPHENYL)]-2-PYRIDINYL-2-ALKYL-PROLINAMIDE AS NK1 RECEPTOR ANTAGONISTS - The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C | 2013-06-06 |
| 20130143932 | OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS - The present invention discloses optically pure (R) and (S) Phenyramidol enantiomers and their pharmaceutically acceptable salts, a process for synthesizing such enantiomers by means of a styrene oxide based synthesis, and also a clinical evaluation of (R) and (S) enantiomers of Phenyramidol, their salts and compositions thereof for enhanced/newer therapeutic benefits. | 2013-06-06 |
| 20130143933 | TARGETED CORRECTION OF A GENETIC DEFECT IN CANCER THERAPY - The present document describes a cancer mutation-selective chemosensitizer that comprise compounds for restoring association between mutated keap1 protein and Nrf2 protein, and inhibition of Nrf2 functions. The present document also describes composition of matter containing the compounds, as well as methods of medical treatment for treating diseases such as cancer with the compounds. | 2013-06-06 |
| 20130143934 | AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES - An EP2 agonist which may have an EP3 agonistic effect has an effect of regenerating and/or protecting nerves, and is therefore useful as a therapeutic agent for a disease of the peripheral nervous system, such as a lower or upper motor neuron disease, a nerve root disease, plexopathy, thoracic outlet compression syndrome, peripheral neuropathy, neurofibromatosis and neuromuscular transmission disease. An EP2 agonist which has an EP3 agonistic effect is a safe and effective agent for the regeneration and/or protection of nerves which has little influence on the circulatory system. | 2013-06-06 |
| 20130143935 | STEM CELL DIFFERENTIATING AGENTS AND USES THEREFOR - The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively. | 2013-06-06 |
| 20130143936 | 2-IMINOBIOTIN FORMULATIONS AND USES THEREOF - The disclosure relates to improving the aqueous solubility of 2-iminobiotin. In a particular aspect, the invention pertains to formulations suitable for administration of 2-iminobiotin to mammals suffering from disorders or conditions that benefit from said administration. | 2013-06-06 |
| 20130143937 | CHLORTHALIDONE COMBINATIONS - The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension. | 2013-06-06 |
| 20130143938 | Compositions and Methods for the Treatment of Migraine - Pharmaceutical compositions for the treatment of nasal congestion or migraine, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective α-2 adrenergic receptor agonists. | 2013-06-06 |
| 20130143939 | IMIDO-ACID SALTS AND METHODS OF USE - Imido-acid salts and compositions containing imido-acid salts are described herein. Methods of their preparation and use are also described herein. The methods of using the imido-acid salts include the reduction of volatile compounds from gas and liquid streams and the delivery of pharmaceutical agents to subjects. | 2013-06-06 |
| 20130143940 | FUNGICIDAL PYRAZOLES - Disclosed are compounds of Formula 1 and Formula 1A including all stereoisomers, N-oxides, and salts thereof, | 2013-06-06 |
| 20130143941 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS - This invention is directed to pharmaceutical compositions for topical administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as an enantiomer, a racemate or a non-racemic mixture, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions. | 2013-06-06 |
| 20130143942 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT APHIDS - The invention relates to a method of controlling aphids that are resistant to neonicotinoid insecticides, using the compound spirotetramat in free form or in agrochemically acceptable salt form as well as the use of compositions comprising said compound to control neonicontinoid resistant insects. In particular the methods relate to controlling neonicotinoid resistant insects in the Aphididae family, that are resistant to one or more neonicotinoid insecticides. Methods of the invention find particular use in controlling neonicotinoid resistant insects in crops of useful plants. Furthermore, the invention extends to methods of controlling plant viruses spread by neonicotinoid resistant insects. | 2013-06-06 |
| 20130143943 | MODULATION OF GLUCOCORTICOID RECEPTOR EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor are provided. | 2013-06-06 |
| 20130143944 | CHEMO- AND RADIATION-SENSITIZATION OF CANCER BY ANTISENSE TRPM-2 OLIGODEOXYNUCLEOTIDES - Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents. | 2013-06-06 |
| 20130143945 | METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES - The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays. | 2013-06-06 |
| 20130143946 | TREATMENT OF DISCS LARGE HOMOLOG (DLG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLG - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG. | 2013-06-06 |
| 20130143947 | Injectable Pharmaceutical Composition for Preventing, Stabilising and/or Inhibiting Pathological Neovascularization-Related Conditions - This invention relates to a pharmaceutical composition for the treatment and/or prevention of at least one pathological neovascularization-related conditions of the interior of the eye, the composition comprising a therapeutically effective amount of an antisens oligonucleotide having the sequence SEQ ID NO: 1: 5′-TCTCCGGAGGGCTCGCCATGCTGCT-3′ or any function conservative sequence comprising from 9 to 30 nucleotides that has 75%, 80%, 85%, 90%, 95% or more than 95%, 96%, 97%, 98%, 99% of identity compared to SEQ ID NO: 1 and that conserves the capacity of inhibiting IRS-1 gene expression as SEQ ID NO: 1, and the composition being administered within the posterior segment of the eye to a subject in need thereof; this invention also relates to a method for treating a pathological neovascularization-related condition of the interior of the eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of said pharmaceutical composition. | 2013-06-06 |
| 20130143948 | MST1 AS A PROGNOSTIC BIOMARKER AND THERAPEUTIC TARGET IN HUMAN CANCER - The present invention relates to MST1 and MST2 cancer biomarkers. The inventors demonstrate herein that MST1 and/or MST2 can be used as biomarkers for the detection and prognosis of prostate cancer. The invention further discloses that enforced expression of MST1 can be used to inhibit and/or suppress the progression of prostate cancer. | 2013-06-06 |
| 20130143949 | G-CSF Transferrin Fusion Proteins - A polypeptide comprising a G-CSF domain operably linked to a Tf domain, wherein the ability of the polypeptide to be transported into a cell expressing a TfR gene or the ability of the polypeptide to be transported across a cell expressing a TfR gene via transcytosis is higher than that of the G-CSF domain alone. | 2013-06-06 |
| 20130143950 | Compounds and Methods for the Treatment of Cancer - The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. | 2013-06-06 |
| 20130143951 | HUMANIZED TTC AND METHODS OF USE THEREOF - Compositions and methods for treating neurological diseases and disorders are disclosed. | 2013-06-06 |
| 20130143952 | IMPAIRED WOUND HEALING COMPOSITIONS AND METHODS - Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles. | 2013-06-06 |
| 20130143953 | Compositions, kits and methods for treatment of complement-related disorders - Methods, compositions and kits for regulating complement activity or treating a complement activity disorder in a subject using soluble, membrane-independent CD59 protein, methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein. | 2013-06-06 |
| 20130143954 | RECOMBINANT VECTOR FOR SUPPRESSING PROLIFERATION OF HUMAN PAPILLOMA VIRUS CELLS INCLUDING ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 1 (PITUITARY) GENE AND PHARMACEUTICAL COMPOSITION FOR TREATING HUMAN PAPILLOMA VIRUS - The present invention relates to a cervical cancer therapeutic agent comprising a recombinant vector containing a gene that encodes adenylate cyclase activating polypeptide 1 (pituitary) (ADCYAP1). The use of the recombinant vector and a pharmaceutical composition comprising the recombinant vector can prevent or treat cervical cancer by inhibiting the proliferation of cervical cancer cells. | 2013-06-06 |
| 20130143955 | Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use - Disclosed are compositions and methods involving cyclic di-GMP—responsive Riboswitches and cyclic di-GMP-II motifs. | 2013-06-06 |
| 20130143956 | LONG-ACTING INJECTABLE MOXIDECTIN FORMULATIONS AND NOVEL MOXIDECTIN CRYSTAL FORMS - This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals. | 2013-06-06 |
| 20130143957 | POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF - There is provided crystalline solvate forms of Warfarin potassium, termed APO-I and APO-II, and processes for making APO-I and APO-II. APO-I and APO-II are polymorphic solvate forms of Warfarin potassium. | 2013-06-06 |
| 20130143958 | DOSAGE UNIT COMPRISING A PROSTAGLANDIN ANALOG FOR TREATING CONSTIPATION - A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in a range of about 6-96 μg: | 2013-06-06 |
| 20130143959 | EXTRACTS WITH LIVER-X-RECEPTOR MODULATORS, COMPOUNDS AND THEIR USE ESPECIALLY IN WEIGHT CONTROL - The invention relates to an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from | 2013-06-06 |
| 20130143960 | NOVEL SEROTONIN REUPTAKE INHIBITORS AS DRUGS HAVING PERIPHERAL-SYSTEM-RESTRICTED ACTIVITY - Serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation. | 2013-06-06 |
| 20130143961 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS - Carbamimidothioic acid esters of formula (I) and 2-nitro-N-[4-(pyridin-4-ylamino)phenyl]-4-(quinolin-4-ylamino)benzamide are used for the treatment of influenza, and for the inhibition of a viral RNA-dependent RNA polymerase. Formulae (I), (II). | 2013-06-06 |
| 20130143962 | Adamantyl Derivatives as Therapeutic Agents - The present invention relates to adamantyl derivatives and their anti-cancer activity. Compounds of formulae I and II are provided as well as related methods of treatment and methods of synthesis. | 2013-06-06 |
| 20130143963 | SULFORAPHANE STABILIZATION - A stable galenic composition of a compound of general formula (I) wherein R | 2013-06-06 |
| 20130143964 | SYMPATHETIC INHIBITOR, AND COSMETIC COMPOSITION, FOOD, AND SUNDRY ARTICLE CONTAINING THE SAME - Disclosed are a sympathetic inhibitor allowing more effective inhibition of activity of a sympathetic nerve, as well as a cosmetic composition, a food, and a sundry article containing the same. Ethyl 4-methoxybenzoate is efficacious for quieting down the activity of the sympathetic nerve. The sympathetic inhibitor, the cosmetic composition, the food and the sundry article containing the same enable more effective inhibition of the activity of the sympathetic nerve. | 2013-06-06 |
| 20130143965 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 2013-06-06 |
| 20130143966 | METHODS OF TREATMENT USING STERCULIC ACID - The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-keto-cholesterol toxicity, and unregulated angiogenesis. | 2013-06-06 |
| 20130143967 | Organosulfur compounds for the prevention and treatment of neurodegenerative diseases - S-allylmercapto-N-acetylcysteine and related compounds are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compounds include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia. | 2013-06-06 |
| 20130143968 | Methods and compositions for the treatment of diabetes and related symtoms - The present invention is directed to methods and compositions for the treatment of diabetes and related symptoms. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diabetes and related symptoms. In a method aspect, the present invention provides a method of treating diabetes. The method involves ingesting 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diabetes. | 2013-06-06 |
| 20130143969 | CURCUMIN COMPOSITIONS AND USES THEREOF - A composition and method of increasing the bioavailability of curcumin is provided. A synergistic combination of excipient polymers provides increased bioavailability thereby increasing the plasma concentration of curcumin and its metabolite curcumin O-glucuronide. The curcumin pharmaceutical compositions are suitable for modifying DNA methylation and treating diseases such as cancer. | 2013-06-06 |
| 20130143970 | MEDICINAL PREPARATION PARTICULARLY FOR THE TREATMENT OF SLIPPED DISCS HERNIAS - The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least tungsten and/or tantalum metal making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas. | 2013-06-06 |
| 20130143971 | PROCESS FOR PRODUCING HYDROCARBON OIL AND SYSTEM FOR PRODUCING HYDROCARBON OIL - Hydrocarbon oil obtained by Fischer-Tropsch synthesis reaction using a slurry bed reactor holding a slurry of a liquid hydrocarbon in which a catalyst is suspended; the hydrocarbon oil is fractionated into a distilled oil and a column bottom oil containing the catalyst fine powder by a rectifying column; at least part of the column bottom oil is transferred to a storage tank, and the catalyst fine powder is sedimented to the bottom of the storage tank to capture the catalyst fine powder; a residue of the column bottom oil is transferred from the rectifying column to a hydrocracker, and/or the supernatant of the column bottom oil from which the catalyst fine powder is captured by the storage tank is transferred from the storage tank to the hydrocracker; and using the hydrocracker, the residue of the column bottom oil and/or the supernatant of the column bottom oil is hydrocracked. | 2013-06-06 |
| 20130143972 | BIOMASS GASIFICATION AND INTEGRATED PROCESSES FOR MAKING INDUSTRIAL CHEMICALS THROUGH AN ACETIC ACID INTERMEDIATE - The invention relates to integrated processes for producing industrial chemicals, such as alcohols, carboxylic acids, esters, aldehydes, olefins and polymers from biomass. In one embodiment, the invention is to a process comprising the steps of (a) introducing biomass and an oxygen stream to a gasifier and converting the biomass into a product gas, wherein the gasifier is operated at a pressure of at least 10 bar; (b) compressing the product gas at a compression ratio that is less than 5:1 to form compressed product gas; (c) directing a first portion of the compressed product gas to an alcohol synthesis reactor to produce methanol; (d) directing a second portion of the compressed product gas to a gas separator to produce a hydrogen stream and a carbon monoxide stream; (e) reacting the carbon monoxide stream with the methanol to produce acetic acid; and (f) reacting the hydrogen stream with acetic acid to produce ethanol. | 2013-06-06 |
| 20130143973 | BIOMASS GASIFICATION AND INTEGRATED PROCESSES FOR MAKING INDUSTRIAL CHEMICALS THROUGH AN ESTER INTERMEDIATE - The invention relates to integrated processes for producing industrial chemicals, such as alcohols, carboxylic acids, esters, aldehydes, olefins and polymers from biomass. In one embodiment, the invention is to a process comprising the steps of: introducing biomass and an oxygen stream to a gasifier and converting the biomass into a product gas, wherein the gasifier is operated at a pressure of at least 10 bar; compressing the product gas at a compression ratio that is less than 3:1 to form a compressed product gas; directing a first portion of the compressed product gas to an alcohol synthesis reactor to produce methanol; reacting carbon monoxide with the methanol to produce acetic acid; esterifying the acetic acid with ethanol to form ethyl acetate; and reducing the ethyl acetate with hydrogen in the presence of a catalyst to form ethanol. | 2013-06-06 |
| 20130143974 | METHOD AND DEVICE FOR THE DECONTAMINATION OF PLASTIC FLAKES - A method for preparing contaminated plastics ground into flakes, such as RPET or such polymers, having at least decontamination and SSP treatment steps, with at least one reactor, with heating to the process temperature taking place essentially outside the reactor. Also, a device for carrying out the method, and having at least one decontamination reactor and at least one SSP reactor, a device for heating plastic flakes to the process temperature being arranged upstream of the decontamination reactor. Also an SSP reactor having at least two individual reactors, and preferably between 3 and 7 individual reactors. | 2013-06-06 |
| 20130143975 | Method of Foaming Polyolefin Using Acrylated Epoxidized Fatty Acid and Foam Produced Therefrom - The presently disclosed subject matter relates generally to method of producing thermoplastic foam from a blend of polyolefin and acrylated epoxidized fatty acid using a phsyical blowing agent. Specifically, the presently disclosed subject matter includes embodiments wherein the acrylated epoxidized fatty acid is added to the polyolefin resin in an amount of from about 0.1% to about 10%, based on the total weight of the resin. The presently disclosed subject matter also includes the foam produced by the disclosed method. | 2013-06-06 |
| 20130143976 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION - A medical device includes a substrate having at least a portion thereof functionalized with at least one reactive member and a chemotactic agent functionalized with at least one complementary reactive member, wherein the at least one reactive member and the at least one complementary reactive member are covalently bonded, adhering the chemotactic agent to the substrate. | 2013-06-06 |
| 20130143977 | Ethylene Oxide/Propylene Oxide Polyether Polyols and Polyurethanes Made Therefrom - Copolymers of propylene oxide and ethylene oxide have an inner block that contains from 65-90 weight percent oxyethylene units and from 10 to 35 weight percent oxypropylene units. This block has a molecular weight of from 150 to 350. The copolymer has an outer block which contains at least 95 weight % oxypropylene units and from 0 to 5% oxyethylene units. The equivalent weight of the copolymer is from 800 to 2000. The copolymers are useful in making polyurethane foams that have unexpectedly high tensile and/or tear strengths. | 2013-06-06 |
| 20130143978 | UV CURABLE COATING COMPOSITION WITH IMPROVED SCRATCH RESISTANCE - Disclosed is a coating composition that when dried and cured, provides a coating composition having excellent scratch and mar resistance. The coating composition is cures upon exposure to ultraviolet radiation. The coating composition comprises a film forming binder that is a polymer having poly(trimethylene ether) repeat units and in the range of from 1 to 20 ethylenically unsaturated double bonds. The coating composition is especially useful as a clearcoat composition in the automotive industry. | 2013-06-06 |
| 20130143979 | PRECURSOR COMPOSITION FOR CROSSLINKABLE PRESSURE-SENSITIVE ADHESIVE FOR SKIN - A composition for production of a crosslinkable pressure-sensitive adhesive for skin, obtained by dissolving in a solvent 100 parts by weight of an acrylic copolymer (copolymer A) comprising a (meth)acrylic acid alkyl ester as the main constituent component and 3-45 wt % diacetoneacrylamide as an essential constituent component, and containing no free carboxyl groups, and 0.1-30 parts by weight of an acrylic copolymer (copolymer B) comprising a (meth)acrylic acid alkyl ester as the main constituent component and a primary amino group and/or carboxyhydrazide group on a side chain, and containing no free carboxyl groups. | 2013-06-06 |
| 20130143980 | MICROSPHERE BASED WALL REPAIR COMPOUND - The present invention is a drying composition comprising spherical beads and a stable aqueous dispersion of polymer particles and also a dried composition of the spherical beads and a polymer film. The composition is useful as a wall repair formulation. | 2013-06-06 |
| 20130143981 | RESIN COMPOSITION, MOLDED OBJECT AND SUBSTRATE MATERIAL BOTH OBTAINED FROM THE RESIN COMPOSITION, AND CIRCUIT BOARD INCLUDING THE SUBSTRATE MATERIAL - To provide a resin composition having excellent thermal conductivity and excellent insulation reliability, a molded object, a substrate material, and a circuit board. [Solution] Provided is a resin composition which comprises an epoxy resin, a hardener, and an inorganic filler, wherein the epoxy resin and/or the hardener has a naphthalene structure, the inorganic filler comprises hexagonal boron nitride, and the inorganic filler accounts for 50-85 vol. % of the whole resin composition. Since a naphthalene structure, which imparts the satisfactory ability to wet the hexagonal boron nitride included in the inorganic filler, has been introduced into the epoxy resin and/or the hardener to heighten the inorganic-filler loading characteristics, this resin composition attains excellent heat dissipation properties, heat resistance, insulating properties, etc. | 2013-06-06 |
| 20130143982 | COATING COMPOSITIONS - A coating composition comprising an advanced epoxy resin polymeric composition having the following chemical structure:(formula) I where n is a number from 1 to about 3000; each m independently has a value of 0 or 1; each R0 is independently —H or —CH | 2013-06-06 |
| 20130143983 | LIQUID RESIN COMPOSITION AND SEMICONDUCTOR DEVICE - According to the invention, a liquid resin composition which has favorable wet spreadability after mounting of a chip and exhibits excellent solder cracking resistance even in a high-temperature solder reflow process at about 260° C., i.e., even when being used in lead-free solder, and a semiconductor package using the liquid resin composition are provided. In the liquid resin composition of the invention, an acrylic copolymer having a radical polymerizable functional group contains alkyl(meth)acrylate as a constituent monomer having a linear or branched alkyl group having 6 to 9 carbon atoms in an amount of 10 wt % to 40 wt % of the entire constituent monomers. | 2013-06-06 |
| 20130143984 | PRODUCTION OF CURED EPOXY RESINS WITH FLAME-RETARDANT PHOSPHONATES - The invention relates to curable compositions which comprise epoxy resins, amino hardeners, and a phosphonate of the formula I. Addition of phosphonate of the formula I can give cured epoxy resins which have not only improved flame retardants but also an increased glass transition temperature when comparison is made with the corresponding resins without said addition. | 2013-06-06 |
| 20130143985 | ASPHALT COMPOSITION CONTAINING GROUND TIRE RUBBER - We disclose a method of making an asphalt composition containing large quantities of ground tire rubber. Over 20% GTR by weight can be used in the asphalt composition without the GTR settling out. The method comprises a series of heating and blending and using a GTR stabilizer. | 2013-06-06 |
| 20130143986 | FILM FORMING COATING COMPOSITIONS CONTAINING CARBOXAMIDE COALESCING SOLVENTS AND METHODS OF USE - A film may be formed from film forming compositions which comprise at least one carboxamide based coalescing solvent. These coalescing solvents impart equivalent or improved wet-scrub resistance, block resistance, gloss, dirt pick-up resistance and leveling characteristics to the films on a substrate, without contributing to total VOC levels, when replacing conventional coalescing solvents. The present invention also includes a method for forming a film comprising applying a film forming composition comprising polyunsaturated reactive carboxamides to a substrate and curing the film under ambient conditions. The coalescing carboxamide solvents are suitable for paint, latex based caulk, adhesives and floor care applications. | 2013-06-06 |
| 20130143987 | METHOD FOR PREPARING SPINNING SOLUTION OF ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE FIBER - Provided is a method for preparing a spinning solution of ultra-high molecular weight polyethylene fiber, which comprises mixing a dissolved solution of ultra-high molecular weight polyethylene with a swollen solution of ultra-high molecular weight polyethylene at a weight ratio of 0.42˜2.85, to obtain a spinning solution with a content of the ultra-high molecular weight polyethylene being 10%˜15% by weight; the content of the ultra-high molecular weight polyethylene in the swollen solution of ultra-high molecular weight polyethylene is 10%˜50% by weight; and the weight ratio of the ultra-high molecular weight polyethylene in the swollen solution of ultra-high molecular weight polyethylene to the ultra-high molecular weight polyethylene in the dissolved solution of ultra-high molecular weight polyethylene is 2.5˜70. Since the dissolved solution functions to plasticize the swollen solution, the problem of high viscosity of the spinning solution is well addressed, thus ensuring that the spinning solution has a good fluidity and spinning continuity, and avoiding broken filament and filament breakage from occurring in the subsequent spinning process, so as to prepare ultra-high molecular weight polyethylene fiber with good performance. | 2013-06-06 |
| 20130143988 | MODIFIED PHYLLOSILICATE - Polymer nanocomposites including: a) a polylactic polymer; and b) a modified phyllosilicate composition including a modifying agent which includes hexadecyl trimethyl ammonium cations which are intercalated between the layers of the phyllosilicate, and preparation processes therefor, as well as the modified phyllosilicate composition. The polymer nanocomposites are particularly useful for packaging, particularly food and drink packaging. | 2013-06-06 |
| 20130143989 | Oil-In-Water Silicone Emulsion Composition - Provided is an oil-in-water silicone emulsion composition that has a low silicone oligomer content, and that can form, even without the use of an organotin compound as a curing catalyst, a cured film that exhibits satisfactory strength and satisfactory adherence to a substrate, through the removal of water fraction. An oil-in-water silicone emulsion composition comprising (A) 100 mass parts of a polyorganosiloxane that contains in each molecule at least two groups selected from the group consisting of a silicon-bonded hydroxyl group, alkoxy group, and alkoxyalkoxy group, (B) 0.1 to 200 mass parts of a colloidal silica, (C) 0.1 to 100 mass parts of an aminoxy group-containing organosilicon compound that has in each molecule an average of two silicon-bonded aminoxy groups, (D) 1 to 100 mass parts of an ionic emulsifying agent, (E) 0.1 to 50 mass parts of a non-ionic emulsifying agent, and (F) 10 to 500 mass parts of water. | 2013-06-06 |
| 20130143990 | PROTECTIVE COATING COMPOSITION - A protective coating composition comprises an acrylic resin, a reactive polyorganosiloxane or precursor therefor, hexamethyldisiloxane, and a solvent system. The coating composition may be applied to surfaces such as painted metal surfaces as may be found in motor vehicles. | 2013-06-06 |
| 20130143991 | WATER-SOLUBLE PRESSURE SENSITIVE ADHESIVES - A water-soluble pressure sensitive adhesive comprises a homogeneous blend comprising (a) a polymer selected from the group consisting of N-vinyl caprolactam homopolymers, N-vinyl pyrrolidone copolymers, and mixtures thereof and (b) a non-volatile plasticizer comprising a monohydric or polyhydric alcohol having hydrophilic-lipophilic balance of about 2 to about 10. The N-vinyl pyrrolidone copolymers comprise about 60% or less by weight N-vinyl pyrrolidone. | 2013-06-06 |
| 20130143992 | MIXTURES RESULTING FROM METHODS FOR PURIFICATION OF POLYETHER POLYMERS - A method for the purification of aromatic polyether polymers prepared by a halide displacement polymerization process comprises adsorbing the catalyst with an alkali metal halide to form an adsorbent component and then removing the adsorbent component. Mixtures resulting from this method are also discussed. | 2013-06-06 |
| 20130143993 | INDICATION OF IMPROPERLY MOLDED PARTS - A method of determining that a thermoplastic was insufficiently dried before forming into a molded plastic part. The method comprises preparing a mixture of a thermoplastic polymer and an off-gassing compound, wherein the off-gassing compound is selected to release all water of hydration in response to target drying conditions specified for the thermoplastic polymer. The mixture is dried at actual drying conditions, and then heated to reduce the viscosity of the thermoplastic polymer and allow the mixture to flow. The mixture is then made to flow into a mold to form a plastic part at a molding temperature, wherein the molding temperature will cause any remaining water of hydration in the off-gas sing compound to off-gas and form surface irregularities in the plastic part. Non-limiting examples of the off-gassing compound include hydrated metal halides and ionic hydrates. | 2013-06-06 |
| 20130143994 | AROMATIC POLYCARBONATE COMPOSITION - A process for producing a circuit carrier comprising at least a moulded part and a circuit carried by the moulded part, wherein the moulded part includes a polycarbonate composition having the following components:
| 2013-06-06 |
